IPAR

IRISH MEDICINES BOARD

PUBLIC ASSESSMENT REPORT FOR A MEDICINAL PRODUCT FOR HUMAN USE

Scientific discussion

Olanzapine 2.5 mg Film-coated Tablets
Olanzapine 5 mg Film-coated Tablets
Olanzapine 7.5 mg Film-coated Tablets
Olanzapine 10 mg Film-coated Tablets
Olanzapine 15 mg Film-coated Tablets
Olanzapine 20 mg Film-coated Tablets

OLANZAPINE

PA688/23/1-6

The Public Assessment Report reflects the scientific conclusion reached by the Irish Medicines Board (IMB) at the end of the evaluation process and provides a summary of the grounds for approval of a marketing authorisation for a specific medicinal product for human use. It is made available by the IMB for information to the public, after deletion of commercially sensitive information. The legal basis for its creation and availability is contained in Article 21 of Directive 2001/83/EC, as amended. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the IMB leading to the approval of the medicinal product for marketing in Ireland.

I INTRODUCTION

Based on the review of the data on quality, safety and efficacy, the IMB has granted a marketing authorisation for olanzapine film coated tablets, from Chanelle Medical on 6th May 2011 for the treatment of schizophrenia.

This application for a marketing authorisation was submitted in accordance with Article 10 of Directive 2001/83/EC and is referred to as generic application. That is a range of olanzapine tablets have the same qualitative and quantitative composition in terms of active substance and the same pharmaceutical form as Zyprexa tablets and whose bioequivalence has been demonstrated to the reference product.. The reference product used is Zyprexa 10mg coated tablets from Eli Lilly authorised on 1996-09-27. The relevant numbers for the various strengths are EU/1/96/022/08, EU/1/96/022/09, EU/1/96/022/10, EU/1/96/022/26 & EU/1/96/022/32.

Olanzapine film-coated tablets are subject to prescription which may not be repeated.

The Summary of Product Characteristics for (SPC) for this medicinal product is available on the IMB's website at http://www.imb.ie/.

Name of the product	Olanzapine film-coated tablet
Name(s) of the active substance(s) (INN)	OLANZAPINE
Pharmacotherapeutic classification (ATC code)	N05AH03
Pharmaceutical form and strength(s)	2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg & 20 mg Film-coated Tablets
Marketing Authorisation Number(s) in Ireland (PA)	PA688/23/1-6
Marketing Authorisation Holder	Chanelle Medical

II QUALITY ASPECTS

II.1. Introduction

This application is for a range six strengths of olanzapine film-coated tablets: 2.5 mg, 5 mg, 7.5 mg, 10mg, 15 mg and 20 mg.

II.2 Drug substance

The active substance is olanzapine, an/established active substance described in the Pharmeuropa, and is manufactured in accordance with the principles of Good Manufacturing Practice (GMP)

The active substance specification is considered adequate to control the quality and meets current pharmacopoeial requirements. Batch analytical data demonstrating compliance with this specification has been provided.

II.3 Medicinal product

P.1 Composition

The product, described below, is a white to off-white film-coated tablet either round or oval in shape.

	Shape	Mark one side	Mark on other side
2.5 mg	round	Plain	2.5
5 mg	round	Plain	5
7.5 mg	round	Plain	7.5
10 mg	round	Plain	10
15 mg	oval	Plain	15
20 mg	oval	Plain	20

P.2 Pharmaceutical Development

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

P.3 Manufacture of the Product

The product is manufactured in accordance with the principles of good manufacturing practice (GMP) at suitably qualified manufacturing sites.

The manufacturing process has been validated according to relevant European/ICH guidelines and the process is considered to be sufficiently validated.

P.4 Control of Other Substances (Excipients*)*

All ingredients comply with Ph. Eur. or are adequately controlled by the manufacturer's specifications.

P.5 Control of Finished Product

The Finished Product Specification is based on the pharmacopoeial monograph for film-coated tablets, and the tests and control limits are considered appropriate for this type of product.

The analytical methods used are described in sufficient detail and are supported by validation data.

Batch analytical data for a number of batches from the proposed production site have been provided, and demonstrate the ability of the manufacturer to produce batches of finished product of consistent quality.

P.6 Packaging material

The product is presented as aluminium /aluminium blister strips packed into outer cardboard cartons..

Evidence has been provided that the blister packaging complies with EU legislation for use with foodstuffs requirements.

P.7 Stability of the Finished Product

Stability data on the finished product in the proposed packaging have been provided in accordance with EU guidelines demonstrating the stability of the product for 3 years with no special storage conditions.

II.4 Discussion on Chemical, Pharmaceutical and Biological Aspects

The important quality characteristics of the product are well-defined and controlled. Satisfactory chemical and pharmaceutical documentation has been provided, assuring consistent quality of olanzapine film-coated tablets.

III NON-CLINICAL ASPECTS

III.1 Introduction

This active substance has been available on the European/Irish market for 14 years. Preclinical data have been superseded by clinical experience and therefore no preclinical assessment report is available.

IV CLINICAL ASPECTS

IV.1 Introduction

Olanzapine is a well known active substance with established efficacy and tolerability.

The content of the SPC approved during the national procedure is in accordance with that accepted for the reference product Zyprexa film coated tablets marketed by Eli Lilly Netherlands B.V.

For this generic application, the applicant has submitted a bioequivalence study in which the pharmacokinetic profile of the test product Olanzapine 5 mg film coated tablets is compared with the pharmacokinetic profile of the reference product Zyprexa 5 mg tilm coated tablets.

A single-dose, randomised, two-period, two-treatment, two-sequence, crossover bioequivalence study was carried out. Olanzapine 5 mg film coated tablets was compared to the reference product Zyprexa 5 mg tilm coated tablets. Based on the pharmacokinetic parameters of active substance, the reference tablet marketed by Eli Lilly Netherlands B.V.and test tablet are bioequivalent with extent to the rate and extent of absorption and fulfil the bioequivalence requirements outlined in the relevant CHMP Note for Guidance.

The IMB has been assured that GCP standards were followed in an appropriate manner in the studies conducted. The schedule for Periodic Safety Update Reports will be on a three yearly basis.

The Marketing Authorisation Holder submitted a set of documents describing the Pharmacovigilance System, including information on the availability of an EU Qualified Person for Pharmacovigilance (EU-QPPV) and the means for notification of adverse reaction reports in the EU or from a Third Country.

IV.6 Discussion on the clinical aspects

Please see overall conclusion below.

V OVERALL CONCLUSIONS

BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

Olanzapine film-coated tablets 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg & 20 mg Film-coated Tablets is a generic form of Zyprexa film coated tablets a well-known medicinal product with a proven chemical-pharmaceutical quality and an established favourable efficacy and safety profile.

Bioequivalence has been shown to be in compliance with the CHMP guidance documents. The SPC is consistent with that of the reference product.

The MAH has provided written confirmation that systems and services are in place to ensure compliance with their pharmacovigilance obligations.

The IMB, on the basis of the data submitted considered that Olanzapine film-coated tablets demonstrated bioequivalence with the reference product as well as a satisfactory risk/benefit profile and therefore granted a marketing authorisation.

VI REVISION DATE

May 2011